Mitochondrial Disease

Mitochondria generate the bulk of cellular ATP through oxidative phosphorylation (OXPHOS) — the electron transport chain (Complexes I–IV) passes electrons from NADH and succinate to oxygen — Complexes I, III and IV pump protons across the inner membrane, while Complex II feeds electrons from succinate without pumping — and Complex V (ATP synthase) uses that proton gradient to phosphorylate ADP. When this machinery fails, the cell cannot meet its energy budget, and the cells that suffer first are the ones that spend the most: post-mitotic, high-demand tissues that cannot simply divide their way out of trouble.

This single fact — energy failure in the most energy-hungry tissues — explains the otherwise bewildering clinical picture. Brain, muscle, heart, retina, cochlea, endocrine pancreas, liver, and kidney dominate the phenotype because they have the highest mitochondrial density and the lowest tolerance for ATP shortfall. It is also why mitochondrial disease is the great mimic of medicine: a patient can present to a neurologist (stroke-like episodes, seizures, ataxia), a cardiologist (cardiomyopathy, conduction block), an endocrinologist (diabetes, short stature), or an ophthalmologist (optic atrophy, ophthalmoplegia) — and the unifying thread is only visible when you step back and ask why multiple unrelated systems are failing at once.

Why the unpredictability? Two features distinguish mitochondrial disease from textbook Mendelian disease:

• It is one of the only human disorders with two genomes in play — the small maternally inherited mitochondrial genome (mtDNA) and the much larger nuclear genome (nDNA) that encodes ~99% of mitochondrial proteins. Either can be the culprit.
• For mtDNA disease, each cell carries many copies of the genome, and a mutation may sit in some copies but not others (heteroplasmy). The same variant can therefore produce no symptoms in one tissue and devastating disease in another, and can shift dramatically from one generation to the next.

Taken together, these mean disease can present at any age and affect any organ, in almost any combination. Disease-causing mutations affect at least 1 in 4,300 adults (Gorman 2015), of which mtDNA mutations alone account for about 1 in 5,000 — making mitochondrial disorders among the most common inherited neurological and metabolic diseases. The practical takeaway: 'think mitochondria' whenever an unexplained multi-system disorder spans organs that share nothing except a high demand for ATP.

The human mitochondrial genome is a compact circular, double-stranded molecule of 16,569 bp encoding just 37 genes: 13 OXPHOS subunit proteins, 22 transfer RNAs, and 2 ribosomal RNAs. Most genes are read from the heavy strand; ND6 and eight tRNAs are on the light strand, and the only sizable noncoding region, the control region (D-loop), holds the heavy-strand origin of replication and the main promoters. Critically, mtDNA encodes only core subunits of the respiratory chain plus the apparatus needed to translate them — nothing else. Everything required to build, run, repair, and replicate the mitochondrion (~1,500 proteins, ~99% of the total) is encoded in the nucleus, translated in the cytosol, and imported. This division of labor is the key to understanding mitochondrial genetics: a single OXPHOS complex is assembled from subunits read off both genomes at once, so a defect in either book of instructions can break the same machine.

Why is mtDNA inherited only from the mother? The egg contributes hundreds of thousands of mitochondria to the zygote; the sperm contributes a few dozen, which are actively tagged with ubiquitin and degraded after fertilization. The result is strict maternal inheritance — an affected father, no matter how high his mutant load, transmits no mtDNA to his children. This is the single most important counseling point that separates mtDNA disease from nuclear disease, and it explains the maternal-line pedigree (diabetes-and-deafness through the mother's relatives) that should immediately raise suspicion. The historic confirmation that an mtDNA point mutation alone could cause neurological disease came from Wallace et al. 1988, who linked the m.11778G>A variant to Leber hereditary optic neuropathy and established the maternal-inheritance paradigm.

The two-genome rule has a clinically useful corollary. When the inheritance pattern is Mendelian (autosomal recessive, autosomal dominant, or X-linked) rather than maternal, the defect is almost always in a nuclear gene — even when the downstream lesion is in the mitochondrion. Some nuclear genes (POLG, TWNK/Twinkle, SLC25A4) maintain mtDNA itself; when they fail, mtDNA accumulates secondary deletions or depletion, producing a mitochondrial phenotype that nonetheless segregates as an autosomal trait. So a maternal pedigree points you toward mtDNA sequencing, while a recessive or dominant pedigree — or sporadic childhood disease — points you toward the nuclear genome, where the majority of pediatric mitochondrial disease actually lives.

Each complex, its genes and its diseases. Complex I has 44 different subunits, 7 of them mtDNA-encoded (MT-ND1–6, MT-ND4L); complex II has 4, all nuclear; complex III 11, with only cytochrome b (MT-CYB) from mtDNA; complex IV 14, with the three catalytic subunits (MT-CO1–3) from mtDNA; and ATP synthase about 18 counting the inhibitor IF1, with MT-ATP6 and MT-ATP8 from mtDNA (Tang 2020). The 13 mtDNA-encoded subunits form the membrane-embedded cores of complexes I, III, IV and V. Nuclear assembly factors carry as much clinical weight as subunits: SURF1, which is not a subunit, is the commonest nuclear cause of COX-deficient Leigh syndrome, and NDUFAF genes cause complex I deficiency, the commonest isolated defect in childhood-onset mitochondrial disease (up to 30%; Fassone & Rahman 2012). SDHA causes complex II-deficient Leigh syndrome, and BCS1L (a complex III assembly factor) causes GRACILE and Björnstad syndromes. MT-ATP6 m.8993T>G shows the threshold at work: NARP at roughly 70–90% heteroplasmy and maternally inherited Leigh syndrome above about 90%, although the boundary is not absolute. Primary CoQ10 deficiency (COQ2, COQ4, COQ8A and others) affects the electron carrier between complexes I/II and III and may respond to CoQ10 supplementation. Finally, the 22 mtDNA tRNAs translate all 13 subunits, so a tRNA variant such as m.3243A>G lowers complexes I, III, IV and V together while sparing the wholly nuclear complex II — the basis of SDH-positive, COX-negative fibers on biopsy.

Unlike the nuclear genome, where you inherit exactly two copies of each gene, mtDNA exists in hundreds to thousands of copies per cell. A pathogenic variant rarely affects all of them. When mutant and wild-type genomes coexist, the cell is heteroplasmic; when every copy is identical, it is homoplasmic. Heteroplasmy is the concept that makes mitochondrial genetics genuinely different — it turns a binary 'mutated or not' question into a continuous dose of dysfunction.

The threshold effect. Because residual wild-type mtDNA continues to make functional OXPHOS complexes, a cell can tolerate a surprising amount of mutant mtDNA before anything goes wrong. Disease only emerges once mutant load exceeds a tissue-specific threshold (~60–90%), above which the surviving wild-type genomes can no longer cover the ATP demand. This is why two relatives carrying the same variant can be asymptomatic and severely affected: it is the proportion, not the mere presence, of the mutation that matters. It also explains the mosaic biopsy — within one muscle, fibers that have crossed threshold stain COX-negative while neighboring fibers below threshold look normal, because heteroplasmy is partitioned cell by cell.

The bottleneck — why offspring are unpredictable. During early oogenesis the mtDNA population in the developing germ cell is dramatically reduced to a small number of segregating units, then re-amplified back to the full complement as the oocyte matures. Sampling a small number of genomes and re-expanding them is, statistically, a random draw — so the heteroplasmy a daughter inherits can differ sharply from her mother's. A mother with 40% heteroplasmy may have children ranging from <5% to >95%. This is not a transmission risk in the Mendelian sense (every child is at risk, but a given child's load can lie anywhere from undetectable to near-homoplasmic — Hellebrekers 2012); it is a severity lottery, and it is the single hardest thing to counsel.

Two practical consequences follow. First, tissue choice matters for diagnosis: blood is convenient but, for several variants (notably m.3243A>G), mutant load drifts downward in blood leukocytes over time through negative selection, so a low blood result can be falsely reassuring — urine epithelium or muscle often carries far higher, more representative heteroplasmy. Second, recurrence risk cannot be quantified precisely for a heteroplasmic mother; counseling deals in broad ranges, not percentages.

A handful of mitochondrial syndromes recur often enough to have earned names and acronyms, and recognizing the pattern is what converts a vague multi-system presentation into a targeted genetic test. But a recurring theme cuts across all of them: the same variant can produce different syndromes, and the same syndrome can arise from different variants. This 'genotype is not phenotype' uncoupling is a direct consequence of heteroplasmy and the threshold effect — the tissues that happen to cross threshold determine which clinical picture you see.

The archetype is m.3243A>G. This single transition in MT-TL1 (the gene for mitochondrial tRNA-Leucine) was first tied to MELAS by Goto et al. 1990 and accounts for ~80% of MELAS. Yet the very same variant, at lower heteroplasmy or in different tissues, instead causes maternally inherited diabetes and deafness (MIDD) or isolated sensorineural hearing loss. One mutation, a spectrum of disease — depending entirely on dose and distribution. Because it sits in a tRNA, it impairs the translation of all thirteen mtDNA-encoded proteins, which is why tRNA mutations tend to produce such broad, multi-system encephalomyopathies rather than a single-complex defect.

The syndromes also illustrate the three mechanistic classes of mtDNA lesion, each with a characteristic inheritance and presentation:

• tRNA point mutations (MELAS / m.3243A>G, MERRF / m.8344A>G) — maternally inherited, heteroplasmic, broadly multi-system because protein synthesis is globally impaired.
• Protein-coding point mutations (LHON / Complex I subunits) — often homoplasmic yet incompletely penetrant, frequently tissue-restricted (the optic nerve in LHON), with a striking male predominance that hints at additional nuclear/hormonal modifiers.
• Large single deletions (Kearns-Sayre, Pearson, CPEO) — usually sporadic, arising de novo in the maternal oocyte rather than transmitted, which is why most KSS patients have no affected relatives. Severity tracks with deletion size and tissue distribution along the KSS → CPEO spectrum.

Mapping a presentation onto the right class — maternal pedigree vs. sporadic, multi-system vs. organ-restricted, point mutation vs. deletion — is what lets you order the correct test (targeted mtDNA sequencing vs. deletion/Southern analysis) and offer meaningful prognostic and reproductive counseling.

There is no single test that confirms or excludes mitochondrial disease, and that is the central diagnostic challenge. Because the underlying problem is energy failure in specific tissues, every line of evidence — biochemical, imaging, histological, molecular — is a sample of the wrong place at the wrong time unless interpreted carefully. The clinician's job is to assemble converging clues rather than chase one definitive result.

Why biochemistry is treacherous. Elevated lactate (and an elevated lactate:pyruvate ratio) reflects backed-up glycolysis when OXPHOS cannot keep up — a logical signature of the disease. But lactate may be normal between metabolic crises, or elevated only in the affected compartment: CSF lactate can be raised while blood lactate is normal, because the brain's energy deficit is not mirrored in the periphery. A normal lactate therefore never excludes the diagnosis; it only fails to confirm it. The same logic governs heteroplasmy testing — for several heteroplasmic variants, notably m.3243A>G, muscle or urine outperforms blood, because the mutant load that matters is the load in the energy-starved tissue, not the load that happens to be measurable in a convenient one. The rule does not extend to the homoplasmic LHON variants or to Pearson syndrome, where blood is adequate.

Why counseling is uniquely hard. Two genomes and heteroplasmy combine to defeat simple risk figures:

• For nuclear mitochondrial disease, counseling is ordinary Mendelian arithmetic: most often autosomal recessive (25% recurrence); 50% for an inherited dominant variant but low for a de novo dominant one; and sex-dependent for X-linked genes such as PDHA1.
• For mtDNA disease, it is not. Inheritance is strictly maternal — an affected father transmits zero risk, which is reassuring and definitive — but a heteroplasmic mother cannot be given a precise recurrence figure because the bottleneck randomizes the heteroplasmy her children inherit. Reproductive options exist (preimplantation testing for some variants; mitochondrial replacement therapy, approved in the UK for severe maternal mtDNA disease, which in Newcastle was done by pronuclear transfer, moving the parents' pronuclei from their own zygote into an enucleated donor zygote; the Newcastle program reported eight children in 2025, some with low-level carryover of the maternal variant, so it is framed as risk reduction), but the counseling must honestly convey uncertainty of severity, not a clean percentage.

Why management is mostly defensive. With few disease-modifying drugs, the practical priorities are to avoid mitochondrial toxins and metabolic stress. The cardinal rule is that valproate is absolutely contraindicated in POLG-related disease — it can precipitate fatal acute liver failure, reported most often in Alpers-Huttenlocher syndrome (the mechanism is not settled; impaired fatty acid oxidation and hepatic mtDNA depletion are proposed), and the label also contraindicates it in children under 2 suspected of a mitochondrial disorder, so POLG status should be considered before valproate in any unexplained epileptic encephalopathy. Other agents that further throttle OXPHOS (metformin → lactic acidosis; aminoglycosides → hearing loss in MT-RNR1 carriers) warrant caution. Beyond drug avoidance, the energy-failure model dictates the rest: prevent prolonged fasting, treat intercurrent illness aggressively with an emergency protocol, and support with cofactors (coenzyme Q10, riboflavin, thiamine, L-carnitine) — interventions aimed at protecting a system that has no reserve. In MELAS, IV L-arginine for an acute stroke-like episode is unproven: it was recommended by the Mitochondrial Medicine Society in 2017 (Parikh 2017) on open-label data, but neither the 2019 international stroke-like-episode consensus (Ng 2019, Wellcome Open Res 4:201) nor the 2026 ERN EURO-NMD/MMS Delphi consensus (Mancuso 2026) endorses it — the latter did not support recommending IV arginine for routine acute use (it remains a case-by-case option on open-label evidence) and judged L-arginine, L-citrulline, L-taurine, CoQ10 and vitamins all unproven pending trials. The same consensus advises starting antiseizure medication promptly when seizures are suspected (even without EEG confirmation), considering IV corticosteroids case by case (evidence largely anecdotal), and not using antiplatelet agents or thrombolysis for a stroke-like episode. Disease-specific therapies now exist for a few disorders: oral deoxynucleosides (doxecitine and doxribtimine) for TK2 deficiency with onset at or before age 12 (FDA approved November 2025), and elamipretide for Barth syndrome (FDA accelerated approval September 2025, patients ≥30 kg). Sonlicromanol entered a phase 3 trial (KHENERFIN) in m.3243A>G disease in April 2026. Cofactors have weak evidence except in specific cofactor-responsive defects: CoQ10 in primary CoQ10 deficiency, riboflavin in riboflavin transporter deficiency (RFVT) and ACAD9 deficiency, and biotin with thiamine in SLC19A3 disease.